¼¼°èÀÇ Á¤¹ÐÀÇ·á ½ÃÀå
Precision Medicine
»óǰÄÚµå : 1659459
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 02¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 93 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,464,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 25,393,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°è Á¤¹ÐÀÇ·á ½ÃÀåÀº 2030³â±îÁö 1,611¾ï ´Þ·¯¿¡ À̸¦ Àü¸Á

2024³â¿¡ 974¾ï ´Þ·¯¿¡ À̸¥ °ÍÀ¸·Î ÃßÁ¤µÇ´Â Á¤¹ÐÀÇ·á ¼¼°è ½ÃÀåÀº 2024-2030³â°£ CAGR 8.7%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 1,611¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ Áø´Ü ¿ëµµ´Â CAGR 8.5%¸¦ ³ªÅ¸³»°í, ºÐ¼® ±â°£ Á¾·á±îÁö 890¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Ä¡·á ¿ëµµ ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£Áß CAGR 9.0%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 250¾ï ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 12.8%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ Á¤¹ÐÀÇ·á ½ÃÀåÀº 2024³â¿¡ 250¾ï ´Þ·¯¿¡ À̸¥ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 413¾ï ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â°£ CAGRÀº 12.8%¸¦ ³ªÅ¸³¾ Àü¸ÁÀÔ´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î¼­´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£Áß CAGRÀº °¢°¢ 4.3%¿Í 7.5%¸¦ ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 5.3%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ Á¤¹ÐÀÇ·á ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ¼ºÀå ÃËÁø¿äÀÎ Á¤¸®

Á¤¹ÐÀÇ·á´Â ¾î¶»°Ô ÀǷḦ À籸¼ºÇϰí Àִ°¡?

Á¤¹ÐÀÇ·á´Â À¯ÀüÀû üÁú, ȯ°æ, ¶óÀÌÇÁ½ºÅ¸ÀÏÀ» ±â¹ÝÀ¸·Î ȯÀÚ °³°³ÀÎÀÇ Æ¯¼º¿¡ ¸Â´Â Ä¡·á¿Í °³ÀÔÀ» ÅëÇØ ÇコÄɾ Çõ¸íÀ» ÀÏÀ¸Å°°í ÀÖ½À´Ï´Ù. Á¤¹ÐÀÇ·á´Â ±âÁ¸ÀÇ È¹ÀÏÀûÀÎ ÀÇ·á Á¢±Ù¹ý°ú´Â ´Þ¸® °Ç°­°ú Áúº´¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â À¯ÀüÀû, ȯ°æÀû, ÇൿÀû ¿äÀÎÀ» ÆÄ¾ÇÇÏ¿© °³ÀÎ ¸ÂÃãÇü ÀǷḦ ÁöÇâÇÕ´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀº º¸´Ù È¿°úÀûÀÎ Ä¡·á, Áúº´ÀÇ Á¶±â ¹ß°ß, ¿¹¹æ Àü·«ÀÇ °³¼±, ±×¸®°í ±Ã±ØÀûÀ¸·Î ȯÀÚÀÇ ¿¹ÈÄ °³¼±À¸·Î À̾îÁý´Ï´Ù.

Á¤¹ÐÀÇ·áÀÇ Áß¿äÇÑ Ãø¸éÀº À¯ÀüüÇп¡ ÃÊÁ¡À» ¸ÂÃß°í ÀÖ´Ù´Â Á¡ÀÔ´Ï´Ù. À¯ÀüÀÚ °Ë»ç´Â ȯÀÚ°¡ ƯÁ¤ ¾à¹°À̳ª Ä¡·á¿¡ ¾î¶»°Ô ¹ÝÀÀÇÒÁö¸¦ °áÁ¤ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ¿¹¸¦ µé¾î, ¾Ï Ä¡·á¿¡¼­ Á¾¾çÀÇ À¯Àüü ÇÁ·ÎÆÄÀϸµÀ» ÅëÇØ Á¾¾ç Àü¹®Àǰ¡ ƯÁ¤ µ¹¿¬º¯À̸¦ ½Äº°Çϰí À̸¦ Ç¥ÀûÀ¸·Î ÇÏ´Â ¸ÂÃãÇü Ä¡·á¸¦ ÅëÇØ ºÎÀÛ¿ëÀ» ÃÖ¼ÒÈ­Çϸ鼭 Ä¡·á È¿°ú¸¦ Çâ»ó½Ãų ¼ö ÀÖ½À´Ï´Ù. Á¤¹ÐÀÇ·á´Â ´ç´¢º´, ½ÉÇ÷°üÁúȯ, ÀÚ°¡¸é¿ªÁúȯ°ú °°Àº ¸¸¼ºÁúȯÀÇ °ü¸®¿¡¼­µµ ȯÀÚ °íÀ¯ÀÇ À¯ÀüÀû À§Çè¿äÀÎÀ» ÆÄ¾ÇÇÏ¿© °³Àκ° ¸ÂÃã Ä¡·á °èȹÀ» ¼ö¸³ÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. Á¤¹ÐÀÇ·á°¡ ¹ßÀüÇÔ¿¡ µû¶ó Ä¡·áÀÇ È¿À²¼ºÀ» ³ôÀ̰í, ½ÃÇàÂø¿À¸¦ ÁÙÀ̸ç, º¸´Ù Àû±ØÀûÀÎ ÀÇ·á Á¢±ÙÀ» °¡´ÉÇÏ°Ô ÇÔÀ¸·Î½á ÀÇ·á ½Ã½ºÅÛÀ» º¯È­½Ãų ¼ö ÀÖ´Â ÀáÀç·ÂÀ» °¡Áö°í ÀÖ½À´Ï´Ù.

¾î¶² ±â¼ú Çõ½ÅÀÌ Á¤¹ÐÀÇ·áÀÇ ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖÀ»±î¿ä?

±â¼ú ¹ßÀüÀº Á¤¹ÐÀÇ·á Çõ¸íÀÇ ÃÖÀü¼±¿¡ ÀÖÀ¸¸ç, À¯ÀüüÇÐ, ºòµ¥ÀÌÅÍ ºÐ¼®, ÀΰøÁö´É(AI), ¹ÙÀÌ¿ÀÅ×Å©³î·¯ÁöÀÇ Çõ½ÅÀÌ ±× ¼ºÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. °¡Àå Áß¿äÇÑ Çõ½Å Áß Çϳª´Â Â÷¼¼´ë ¿°±â¼­¿­ ºÐ¼®±â(NGS)´Ù. Â÷¼¼´ë ¿°±â¼­¿­ ºÐ¼®±â(NGS)´Â ÇÑ »ç¶÷ÀÇ À¯Àüü ¿°±â¼­¿­À» ºÐ¼®ÇÏ´Â µ¥ ÇÊ¿äÇÑ ºñ¿ë°ú ½Ã°£À» Å©°Ô ÁÙ¿´À¸¸ç, NGS ±â¼úÀº Á¾ÇÕÀûÀÎ À¯Àüü ÇÁ·ÎÆÄÀϸµÀ» °¡´ÉÇÏ°Ô ÇÏ¿© ÀÇ·áÁøÀÌ Áúº´°ú °ü·ÃµÈ ƯÁ¤ À¯ÀüÀÚ º¯À̸¦ ½Äº°ÇÒ ¼ö ÀÖ°Ô ÇØÁÝ´Ï´Ù. µ¹¿¬º¯À̸¦ ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù. À¯Àüü µ¥ÀÌÅÍ´Â ¾Ï, Èñ±Í À¯Àü¼º Áúȯ ¹× ±âŸ À¯ÀüÀû ¿äÀÎÀÌ ÀÖ´Â ÁúȯÀ» ¾Î°í Àִ ȯÀÚµéÀ» À§ÇÑ ¸ÂÃãÇü Ä¡·á °èȹÀ» ¼ö¸³ÇÏ´Â µ¥ Á¡Á¡ ´õ ¸¹ÀÌ È°¿ëµÇ°í ÀÖ½À´Ï´Ù.

AI¿Í ¸Ó½Å·¯´× ¿ª½Ã Á¤¹ÐÀÇ·á¿¡¼­ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. AI ¾Ë°í¸®ÁòÀº º¹ÀâÇÑ À¯ÀüÀÚ ¹× ÀÓ»ó µ¥ÀÌÅ͸¦ ¼±º°ÇÏ¿© ƯÁ¤ Áúº´°ú °ü·ÃµÈ ¹ÙÀÌ¿À¸¶Ä¿¸¦ ½Äº°Çϰí, Á¶±â Áø´Ü ¹× Ä¡·á Á¢±ÙÀ» °¡´ÉÇÏ°Ô ÇÏ´Â º¹ÀâÇÑ À¯ÀüÀÚ ¹× ÀÓ»ó µ¥ÀÌÅ͸¦ ºÐ¼®ÇÏ¿© ƯÁ¤ Áúº´°ú °ü·ÃµÈ ¹ÙÀÌ¿À¸¶Ä¿¸¦ ½Äº°ÇÕ´Ï´Ù. ¹ÙÀÌ¿À¸¶Ä¿¸¦ ½Äº°ÇÏ¿© Á¶±â Áø´Ü°ú º¸´Ù Ÿ°ÙÆÃµÈ Ä¡·á Á¢±ÙÀ» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. Á¾¾çÇп¡¼­ AI´Â À¯ÀüÀÚ ÇÁ·ÎÆÄÀÏÀ» ±â¹ÝÀ¸·Î ȯÀÚ¸¦ °¡Àå È¿°úÀûÀÎ ¾Ï Ä¡·á¹ý¿¡ ¸Â°Ô Á¶Á¤ÇÏ¿© »ýÁ¸À²À» ³ôÀ̰í ħ½ÀÀû Ä¡·áÀÇ Çʿ伺À» ÁÙÀÌ´Â µ¥ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù.

ºòµ¥ÀÌÅÍ ºÐ¼®ÀÇ ºÎ»óµµ Á¤¹ÐÀÇ·áÀÇ ¶Ç ´Ù¸¥ Áß¿äÇÑ ÃËÁø¿äÀÎÀÔ´Ï´Ù. ¿þ¾î·¯ºí ±â±â, EHR, ȯÀÚ ¸ð´ÏÅ͸µ ½Ã½ºÅÛ¿¡¼­ °Ç°­ µ¥ÀÌÅÍÀÇ °¡¿ë¼ºÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ¿¬±¸ÀÚµéÀº ´ë±Ô¸ð ȯÀÚ±ºÀÇ ½Ç½Ã°£ µ¥ÀÌÅ͸¦ ºÐ¼®ÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ÀÌ µ¥ÀÌÅÍ´Â Áúº´ÀÇ ÁøÇà, Ä¡·á ¹ÝÀÀ, °Ç°­¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ȯ°æ ¹× »ýȰ½À°ü ¿äÀο¡ ´ëÇÑ ±ÍÁßÇÑ ÅëÂû·ÂÀ» Á¦°øÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ Á¤º¸¸¦ À¯ÀüÀÚ µ¥ÀÌÅÍ¿Í ÅëÇÕÇÔÀ¸·Î½á °³¹ßÀÚ´Â °³º° ȯÀÚ¿¡°Ô º¸´Ù Á¾ÇÕÀûÀÌ°í ¸ÂÃã Ä¡·á °èȹÀ» ¼ö¸³ÇÒ ¼ö ÀÖ½À´Ï´Ù.

¶ÇÇÑ, CRISPR-Cas9¿Í °°Àº À¯ÀüÀÚ ÆíÁý ±â¼ú°ú °°Àº »ý¸í°øÇÐ ±â¼úÀÇ ¹ßÀüÀº Á¤¹ÐÀÇ·á¿¡ »õ·Î¿î ±æÀ» ¿­¾îÁÖ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀº ȯÀÚÀÇ À¯ÀüÀÚÄڵ忡 Á¤È®ÇÑ ¼öÁ¤À» °¡ÇÒ ¼ö ÀÖ¾î À¯Àü ÁúȯÀ» ±Ùº»ÀûÀ¸·Î Ä¡·áÇÒ ¼ö ÀÖ´Â °¡´É¼ºÀ» Á¦°øÇÕ´Ï´Ù. ƯÁ¤ À¯ÀüÀÚ º¯ÀÌ ¶Ç´Â ¸é¿ª ¹ÝÀÀÀ» Ç¥ÀûÀ¸·Î ÇÏ´Â À¯ÀüÀÚ Ä¡·á¿Í ¸ÂÃãÇü ¹é½Åµµ ¾Ï, °¨¿° ¹× ±âŸ º¹ÀâÇÑ Áúº´À» ÅðÄ¡ÇÏ´Â °­·ÂÇÑ µµ±¸·Î ºÎ»óÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀº Á¤¹ÐÀÇ·áÀÇ Ã¤ÅÃÀ» °¡¼ÓÈ­ÇÏ¿© ´õ ¸¹Àº ȯÀÚµéÀÌ ´õ ½±°Ô Á¢±ÙÇÏ°í ´õ È¿°úÀûÀ¸·Î »ç¿ëÇÒ ¼ö ÀÖµµ·Ï µ½°í ÀÖ½À´Ï´Ù.

±ÔÁ¦ ´ç±¹ÀÇ Áö¿ø°ú ¼ÒºñÀÚ ¼ö¿ä´Â ¾î¶»°Ô Á¤¹ÐÀǷḦ ÃËÁøÇϰí Àִ°¡?

Á¤¹ÐÀÇ·á ½ÃÀåÀº ±ÔÁ¦ ´ç±¹ÀÇ Áö¿ø°ú °³ÀÎ ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ ¼ÒºñÀÚ ¼ö¿ä Áõ°¡·Î ÀÎÇØ Å« ¿µÇâÀ» ¹Þ°í ÀÖ½À´Ï´Ù. Àü ¼¼°è Á¤ºÎ¿Í ±ÔÁ¦ ±â°üÀº Á¤¹ÐÀÇ·á°¡ ÀÇ·á °á°ú¸¦ °³¼±ÇÏ°í ºñ¿ëÀ» Àý°¨ÇÒ ¼ö ÀÖ´Â °¡´É¼ºÀ» ÀÎÁ¤Çϰí ÀÖ½À´Ï´Ù. ¹Ì±¹¿¡¼­´Â 2015³â¿¡ ½ÃÀÛµÈ Á¤¹ÐÀÇ·á ÀÌ´Ï¼ÅÆ¼ºê(PMI)°¡ °³ÀÎ ¸ÂÃãÇü Ä¡·áÀÇ È®´ë¿Í ÀÇÇÐ ¿¬±¸ÀÇ ÁøÀüÀ» À§ÇØ ¿¬±¸°³¹ß¿¡ ´ëÇÑ ¸·´ëÇÑ ÅõÀÚ¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¸¶Âù°¡Áö·Î À¯·´¿¡¼­´Â À¯·´ÀǾàǰû(EMA) µî ±ÔÁ¦±â°üÀÌ Æ¯È÷ ¾Ï, Èñ±ÍÁúȯ, ¸¸¼ºÁúȯ¿¡ ´ëÇÑ Á¤¹ÐÄ¡·áÁ¦ °³¹ßÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ³ë·ÂÀº ¹Î°ü Çù·ÂÀ» ÃËÁøÇÏ¿© Á¤¹ÐÀÇ·á ±â¼ú °³¹ß ¹× ½ÂÀÎÀ» °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù.

±ÔÁ¦ ´ç±¹µµ Á¤¹Ð Ä¡·á ¹× Áø´Ü µµ±¸ÀÇ ½ÂÀÎ ÀýÂ÷¸¦ °£¼ÒÈ­Çϱâ À§ÇØ ³ë·ÂÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, ¹Ì±¹ ½ÄǰÀǾ౹(FDA)Àº µ¿¹Ý Áø´Ü ¾àǰÀÇ ½Å¼ÓÇÑ ½É»ç¸¦ À§ÇÑ °æ·Î¸¦ ¸¶·ÃÇß½À´Ï´Ù. µ¿¹ÝÁø´Ü¾àÀº Á¾Á¾ Ç¥ÀûÄ¡·áÁ¦¿Í ÇÔ²² »ç¿ëµÇ¸ç, ÀÓ»óÀǰ¡ ȯÀÚÀÇ À¯ÀüÀÚ ÇÁ·ÎÆÄÀÏ¿¡ µû¶ó Ä¡·á¸¦ Á¶Á¤ÇÒ ¼ö ÀÖµµ·Ï Çϱ⠶§¹®¿¡ Á¤¹ÐÀÇ·áÀÇ Áß¿äÇÑ ¿ä¼ÒÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ±ÔÁ¦Àû Áö¿øÀº Á¦¾àȸ»çµéÀÌ º¸´Ù °³ÀÎÈ­µÈ Ä¡·á¹ý°ú Áø´Ü¾à °³¹ß¿¡ ÅõÀÚÇϵµ·Ï Àå·ÁÇÏ¿© ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

¼ÒºñÀÚ Ãø¸é¿¡¼­´Â ȯÀÚµéÀÌ ÀÚ½ÅÀÇ °Ç°­¿¡ ´ëÇØ ´õ ¸¹Àº Á¤º¸¸¦ ¾ò°í °³Àκ° ¸ÂÃã Ä¡·á¸¦ ¿øÇÏ°Ô µÇ¸é¼­ °³ÀÎ ¸ÂÃãÇü ÇコÄÉ¾î ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, 23andMe³ª AncestryDNA¿Í °°ÀÌ ¼ÒºñÀÚ¿¡°Ô Á÷Á¢ÀûÀ¸·Î Á¦°øµÇ´Â À¯ÀüÀÚ °Ë»ç ¼­ºñ½ºÀÇ µîÀåÀº °³ÀÎÀÇ À¯Àü°ú ±×°ÍÀÌ °Ç°­¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» ÀÌÇØÇÏ´Â °Í¿¡ ´ëÇÑ ´ëÁßÀÇ °ü½ÉÀ» ºÒ·¯ÀÏÀ¸Ä×½À´Ï´Ù. ȯÀÚµéÀº ´õ ³ªÀº Ä¡·á °á°ú¿Í ºÎÀÛ¿ëÀÌ ÀûÀº ¸ÂÃãÇü Ä¡·á °èȹÀ» ¹Þ±â À§ÇØ À¯ÀüÀÚ °Ë»ç¸¦ ¹Þ°í ÀÚ½ÅÀÇ °Ç°­ µ¥ÀÌÅ͸¦ °øÀ¯ÇÏ´Â µ¥ Àû±ØÀûÀ¸·Î ³ª¼­°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, Á¾¾çÇÐ ºÐ¾ß¿¡¼­´Â »ýÁ¸À²°ú »îÀÇ ÁúÀ» °³¼±ÇÒ ¼ö Àִ ǥÀû Ä¡·á¹ýÀ» ã±â À§ÇØ È¯ÀÚ¿Í º¸È£ÀÚµéÀÌ À¯Àüü °Ë»ç¸¦ ¿ËÈ£ÇÏ´Â °æÇâÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

¶ÇÇÑ, ¾Ï, ´ç´¢º´, ½ÉÇ÷°ü Áúȯ°ú °°Àº ¸¸¼ºÁúȯ Áõ°¡·Î ÀÎÇØ º¸´Ù Á¤È®Çϰí È¿°úÀûÀÎ Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. Á¤¹ÐÀÇ·á´Â À¯ÀüÀû, ȯ°æÀû, »ýȰ½À°üÀû ¿äÀÎÀ» °í·ÁÇÏ¿© ÀÌ·¯ÇÑ Áúº´ÀÇ º¹À⼺À» ÇØ°áÇÒ ¼ö ÀÖ´Â ¼Ö·ç¼ÇÀ» Á¦°øÇÕ´Ï´Ù. ÇコÄÉ¾î ½Ã½ºÅÛÀÌ ´õ ³·Àº ºñ¿ëÀ¸·Î ´õ ³ªÀº Ä¡·á °á°ú¸¦ Á¦°øÇÏ´Â µ¥ ÁßÁ¡À» µÐ °¡Ä¡ ±â¹Ý Ä¡·á ¸ðµ¨·Î ÀüȯÇÏ´Â °¡¿îµ¥, Á¤¹ÐÀÇ·á´Â Ä¡·á È¿°ú¸¦ ³ôÀÌ°í ºÒÇÊ¿äÇÑ ½Ã¼úÀ» ÁÙÀ̸ç ÀÇ·á ºñ¿ëÀ» ÃÖ¼ÒÈ­ÇÏ´Â ¹æ¹ýÀ¸·Î ÁÖ¸ñ¹Þ°í ÀÖ½À´Ï´Ù. ±ÔÁ¦ÀÇ ¿µÇâ, ±â¼ú Çõ½Å, ¼ÒºñÀÚ ¼ö¿ä Áõ°¡¿Í ÇÔ²² Á¤¹ÐÀÇ·á ½ÃÀåÀº ¹ßÀüÇϰí ÀÖÀ¸¸ç, ÇコÄɾîÀÇ ¹Ì·¡¿¡ ±¤¹üÀ§ÇÑ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù.

Á¤¹ÐÀÇ·á ½ÃÀåÀÇ ÁÖ¿ä ¼ºÀå ÃËÁø¿äÀÎÀº ¹«¾ùÀΰ¡?

Á¤¹ÐÀÇ·á ½ÃÀåÀº ±â¼ú ¹ßÀü, ÀÇ·áºñ ÁöÃâ Áõ°¡, °³ÀÎ ¸ÂÃãÇü Ä¡·á¿¡ ´ëÇÑ °ü½É Áõ°¡·Î ÀÎÇØ ºü¸£°Ô ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. ÁÖ¿ä ¼ºÀå ¿äÀÎ Áß Çϳª´Â À¯Àüü ¿°±â¼­¿­ ºÐ¼®ÀÇ ºñ¿ë °¨¼Ò·Î ÀÎÇØ À¯ÀüÀÚ °Ë»ç°¡ ´õ ¸¹Àº »ç¶÷µé¿¡°Ô Ä£¼÷ÇÏ°Ô ´Ù°¡°¥ ¼ö ÀÖ°Ô µÈ °ÍÀÔ´Ï´Ù. ÀüÀåÀ¯Àüü ½ÃÄö½ÌÀÇ °¡°ÝÀÌ Áö¼ÓÀûÀ¸·Î Ç϶ôÇÔ¿¡ µû¶ó, ´õ ¸¹Àº ȯÀÚ¿Í ÀÇ·áÁøÀÌ À¯ÀüÀû µ¥ÀÌÅ͸¦ Ä¡·á ¹æÄ§À» °áÁ¤ÇÏ´Â µ¥ Ȱ¿ëÇϰí ÀÖÀ¸¸ç, ƯÈ÷ À¯ÀüÀÚ º¯À̰¡ Ä¡·á ¼±Åÿ¡ ¿µÇâÀ» ¹ÌÄ¡´Â Á¾¾çÇÐ ºÐ¾ß¿¡¼­ ´õ¿í ¸¹Àº ȯÀÚ¿Í ÀÇ·áÁøÀÌ À̸¦ Ȱ¿ëÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¯È­´Â Á¤¹Ð Ä¡·á ¹× µ¿¹Ý Áø´Ü ½ÃÀåÀ» È®´ëÇÏ¿© Á¦¾à ¹× ¹ÙÀÌ¿ÀÅ×Å© ±â¾÷µé¿¡°Ô »õ·Î¿î ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù.

¸¸¼ºÁúȯ Áõ°¡µµ Á¤¹ÐÀÇ·á ½ÃÀåÀÇ Áß¿äÇÑ ÃËÁø¿äÀÎÀÔ´Ï´Ù. ¾Ï, ´ç´¢º´, ½ÉÇ÷°ü Áúȯ, ±âŸ ¸¸¼º ÁúȯÀÇ À¯º´·üÀÌ Àü ¼¼°èÀûÀ¸·Î Áö¼ÓÀûÀ¸·Î Áõ°¡ÇÔ¿¡ µû¶ó º¸´Ù È¿°úÀûÀ̰í Ç¥ÀûÈ­µÈ Ä¡·á¹ý¿¡ ´ëÇÑ ¿ä±¸°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. Á¤¹ÐÀÇ·á´Â ÀÌ·¯ÇÑ ÁúȯÀ» ¾Î°í Àִ ȯÀڵ鿡°Ô º¸´Ù ¸ÂÃãÈ­µÈ Ä¡·á¸¦ Á¦°øÇϰí, Ä¡·á °á°ú¸¦ °³¼±Çϸç, ±âÁ¸ Ä¡·áÀÇ ½ÃÇàÂø¿À¸¦ ÁÙÀÏ ¼ö ÀÖ´Â °¡´É¼ºÀ» Á¦°øÇÕ´Ï´Ù. ¿¹¸¦ µé¾î, Á¾¾çÇп¡¼­ Á¤¹ÐÀÇ·á´Â ƯÁ¤ ¾ÏÀ» À¯¹ßÇÏ´Â µ¹¿¬º¯À̸¦ °ø°ÝÇϴ ǥÀû Ä¡·áÁ¦ÀÇ °³¹ß·Î À̾îÁ® ±âÁ¸ È­Çпä¹ý¿¡ ºñÇØ ´õ È¿°úÀûÀÌ°í µ¶¼ºÀÌ ³·Àº Ä¡·á¸¦ °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù.

Á¦¾à»çµéµµ Ç¥ÀûÄ¡·áÁ¦ ¹× Á¤¹ÐÄ¡·áÁ¦ °³¹ß¿¡ ¸¹Àº ÅõÀÚ¸¦ Çϸ鼭 ½ÃÀå ¼ºÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ¹ÙÀÌ¿À¸¶Ä¿¿Í µ¿¹Ý Áø´Ü ¾à¹°ÀÇ °³¹ßÀÌ ÁøÇàµÊ¿¡ µû¶ó, Á¦¾à»çµéÀº ƯÁ¤ À¯ÀüÀÚ ¹× ºÐÀÚ ÇÁ·ÎÆÄÀÏ¿¡ ¸Â´Â Ä¡·á¹ýÀ» ¼³°èÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ÀÌ·¯ÇÑ Ç¥ÀûÈ­µÈ Á¢±Ù ¹æ½ÄÀº ¼º°øÀûÀÎ ÀÓ»ó °á°úÀÇ °¡´É¼ºÀ» ³ôÀ̰í, ºÎÀÛ¿ëÀÇ À§ÇèÀ» ÁÙÀ̸ç, º¸´Ù È¿À²ÀûÀÎ ÀǾàǰ °³¹ß ÇÁ·Î¼¼½º·Î À̾îÁý´Ï´Ù. ¶ÇÇÑ, ƯÁ¤ ȯÀÚ±ºÀ» Ä¡·áÇϱâ À§ÇØ °í¾ÈµÈ ¸é¿ª¿ä¹ý ¹× À¯ÀüÀÚ Ä¡·áÀÇ µîÀåÀº ´Ù¾çÇÑ Ä¡·á ¿µ¿ª¿¡¼­ Á¤¹ÐÀÇ·áÀÇ Àû¿ëÀ» È®´ëÇÏ´Â µ¥ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

¸¶Áö¸·À¸·Î, ÀΰøÁö´É(AI)°ú ¸Ó½Å·¯´×ÀÇ ÇコÄÉ¾î ºÐ¾ß·ÎÀÇ ÅëÇÕÀº Á¤¹ÐÀÇ·áÀÇ µµÀÔÀ» °¡¼ÓÈ­Çϰí ÀÖÀ¸¸ç, AI ±â¹Ý µµ±¸´Â ÀÓ»óÀÇ¿Í ¿¬±¸ÀÚµéÀÌ À¯ÀüÀÚ Á¤º¸, ÀÓ»ó ±â·Ï, »ýȰ½À°ü µ¥ÀÌÅÍ¿Í °°Àº ´ë±Ô¸ð µ¥ÀÌÅÍ ¼¼Æ®¸¦ ºÐ¼®ÇÏ¿© °³º° ȯÀÚ¿¡°Ô °¡Àå È¿°úÀûÀÎ Ä¡·á¹ýÀ» °³º° ȯÀÚ¿¡°Ô °¡Àå È¿°úÀûÀÎ Ä¡·á¹ýÀ» ã¾Æ³»´Â µ¥ µµ¿òÀ» ÁÖ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀº Áø´ÜÀÇ ¼Óµµ¿Í Á¤È®¼ºÀ» Çâ»ó½ÃÄÑ Á¶±â °³ÀÔ°ú ¸ÂÃã Ä¡·á °èȹÀ» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. ¿þ¾î·¯ºí ±â±â ¹× ¸ð¹ÙÀÏ °Ç°­ ¿ëµµ¸¦ ÅëÇÑ °Ç°­ µ¥ÀÌÅÍÀÇ °¡¿ë¼ºÀÌ ³ô¾ÆÁü¿¡ µû¶ó ȯÀÚ Çൿ¿¡ ´ëÇÑ ±ÍÁßÇÑ ÅëÂû·ÂÀ» ¾òÀ» ¼ö ÀÖ¾î º¸´Ù Á¾ÇÕÀûÀ̰í Áö¼ÓÀûÀÎ °Ç°­ °á°ú ¸ð´ÏÅ͸µÀÌ °¡´ÉÇØÁ³½À´Ï´Ù.

ÇコÄÉ¾î »ê¾÷ÀÌ °³ÀÎ ¸ÂÃãÇü Ä¡·á¿Í ±â¼ú ±â¹Ý ¼Ö·ç¼ÇÀ» Áö¼ÓÀûÀ¸·Î ¿ì¼±½ÃÇÔ¿¡ µû¶ó Á¤¹ÐÀÇ·á ½ÃÀåÀº ÇâÈÄ ¸î ³âµ¿¾È Å©°Ô ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ·¯ÇÑ ¼ºÀå ¿äÀÎÀº À¯Àüü, AI, ¹ÙÀÌ¿ÀÅ×Å©³î·¯ÁöÀÇ Áö¼ÓÀûÀÎ ¹ßÀü°ú ÇÔ²² º¸´Ù Ÿ°ÙÆÃµÇ°í È¿°úÀûÀΠȯÀÚ Áß½ÉÀûÀÎ ÇコÄÉ¾î ¼Ö·ç¼ÇÀÇ ±æÀ» ¿­¾îÁÖ°í ÀÖ½À´Ï´Ù.

ºÎ¹®

ÃÖÁ¾ ¿ëµµ(Áø´Ü, Ä¡·á), ÃÖÁ¾ ¿ëµµ(ÀÓ»ó½ÇÇè½Ç, º´¿ø, ȨÄɾî, ±âŸ ÃÖÁ¾ ¿ëµµ)

Á¶»ç ´ë»ó ±â¾÷ ¿¹(ÃÑ 42°³»ç)

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Precision Medicine Market to Reach US$161.1 Billion by 2030

The global market for Precision Medicine estimated at US$97.4 Billion in the year 2024, is expected to reach US$161.1 Billion by 2030, growing at a CAGR of 8.7% over the analysis period 2024-2030. Diagnostics Application, one of the segments analyzed in the report, is expected to record a 8.5% CAGR and reach US$89.0 Billion by the end of the analysis period. Growth in the Therapeutics Application segment is estimated at 9.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$25.0 Billion While China is Forecast to Grow at 12.8% CAGR

The Precision Medicine market in the U.S. is estimated at US$25.0 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$41.3 Billion by the year 2030 trailing a CAGR of 12.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.3% and 7.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.3% CAGR.

Global Precision Medicine Market - Key Trends & Drivers Summarized

How Is Precision Medicine Reshaping Healthcare?

Precision medicine is revolutionizing healthcare by tailoring medical treatments and interventions to individual patients based on their genetic makeup, environment, and lifestyle. Unlike traditional "one-size-fits-all" approaches to medicine, precision medicine aims to customize healthcare by identifying the genetic, environmental, and behavioral factors that influence health and disease. This approach allows for more effective treatments, earlier disease detection, and improved prevention strategies, ultimately leading to better patient outcomes.

A key aspect of precision medicine is its focus on genomics, where genetic testing helps determine how patients will respond to certain medications or treatments. For example, in cancer treatment, genomic profiling of tumors allows oncologists to identify specific mutations that can be targeted with tailored therapies, improving the effectiveness of treatments while minimizing side effects. Precision medicine also plays a critical role in managing chronic diseases such as diabetes, cardiovascular conditions, and autoimmune disorders by identifying patients' unique genetic risk factors and developing personalized treatment plans. As precision medicine advances, it holds the potential to transform healthcare systems by making treatments more efficient, reducing trial-and-error prescribing, and enabling more proactive healthcare approaches.

What Technological Innovations Are Driving The Growth Of Precision Medicine?

Technological advancements are at the forefront of the precision medicine revolution, with innovations in genomics, big data analytics, artificial intelligence (AI), and biotechnology driving its growth. One of the most significant breakthroughs is in next-generation sequencing (NGS), which has drastically reduced the cost and time required to sequence a person’s genome. NGS technology allows for comprehensive genomic profiling, enabling healthcare providers to identify specific genetic mutations associated with diseases, which can then be targeted with precision therapies. Genomic data is being increasingly used to develop personalized treatment plans for patients with cancer, rare genetic disorders, and other conditions that have a genetic component.

AI and machine learning are also playing a crucial role in the precision medicine landscape. These technologies are helping researchers and clinicians analyze vast datasets, such as patient genomes, electronic health records (EHRs), and clinical trial results, to identify patterns and predict treatment outcomes. AI algorithms can sift through complex genetic and clinical data to pinpoint biomarkers associated with specific diseases, enabling earlier diagnosis and more targeted treatment approaches. In oncology, AI is being used to match patients with the most effective cancer therapies based on their genetic profiles, improving survival rates and reducing the need for invasive treatments.

The rise of big data analytics is another key driver in precision medicine. With the growing availability of health data from wearable devices, EHRs, and patient monitoring systems, researchers can now analyze real-time data from large patient populations. This data can reveal valuable insights into disease progression, treatment responses, and the environmental or lifestyle factors that influence health. By integrating this information with genetic data, precision medicine practitioners can develop more holistic and personalized treatment plans for individual patients.

Furthermore, advancements in biotechnology, such as gene editing technologies like CRISPR-Cas9, are opening new avenues for precision medicine. These technologies allow for precise modifications to a patient’s genetic code, offering the potential to treat genetic diseases at their source. Gene therapies and personalized vaccines, which target specific genetic mutations or immune responses, are also emerging as powerful tools in the fight against cancer, infectious diseases, and other complex conditions. These technological innovations are accelerating the adoption of precision medicine, making it more accessible and effective for a wider range of patients.

How Are Regulatory Support And Consumer Demand Driving Precision Medicine?

The precision medicine market is being significantly influenced by regulatory support and increasing consumer demand for personalized healthcare. Governments and regulatory bodies worldwide are recognizing the potential of precision medicine to improve healthcare outcomes and reduce costs. In the United States, the Precision Medicine Initiative (PMI), launched in 2015, has driven substantial investment in research and development, with the aim of expanding personalized treatments and advancing medical research. Similarly, in Europe, regulatory agencies such as the European Medicines Agency (EMA) are promoting the development of precision therapies, particularly in oncology, rare diseases, and chronic conditions. These initiatives are fostering collaboration between public and private sectors, accelerating the development and approval of precision medicine technologies.

Regulatory agencies are also working to streamline the approval process for precision therapies and diagnostic tools. For instance, the U.S. Food and Drug Administration (FDA) has established pathways to expedite the review of companion diagnostics, which are essential for identifying patients who are likely to benefit from specific treatments. Companion diagnostics, often used alongside targeted therapies, are critical components of precision medicine, as they enable clinicians to tailor treatments based on patients’ genetic profiles. This regulatory support is encouraging pharmaceutical companies to invest in the development of more personalized therapies and diagnostics, further driving market growth.

On the consumer side, there is a growing demand for personalized healthcare solutions, as patients become more informed about their health and increasingly seek treatments that are tailored to their individual needs. The rise of direct-to-consumer genetic testing services, such as 23andMe and AncestryDNA, has sparked public interest in understanding personal genetics and its impact on health. Patients are more willing to undergo genetic testing and share their health data to receive tailored treatment plans that offer better outcomes and fewer side effects. In oncology, for instance, patients and caregivers are increasingly advocating for genomic testing to identify targeted therapies that may improve survival and quality of life.

Additionally, the increasing prevalence of chronic diseases, such as cancer, diabetes, and cardiovascular diseases, is driving the demand for more precise and effective treatments. Precision medicine offers solutions that can address the complexities of these conditions by considering genetic, environmental, and lifestyle factors. As healthcare systems shift toward value-based care models, where the focus is on delivering better outcomes at lower costs, precision medicine is being seen as a way to enhance treatment efficacy, reduce unnecessary procedures, and minimize healthcare spending. The combination of regulatory support, technological innovation, and rising consumer demand is propelling the precision medicine market forward, with wide-ranging implications for the future of healthcare.

What Are The Key Growth Drivers In The Precision Medicine Market?

The precision medicine market is experiencing rapid growth, driven by a combination of technological advancements, increased healthcare spending, and a growing emphasis on personalized treatments. One of the primary growth drivers is the declining cost of genomic sequencing, which is making genetic testing more accessible to a larger population. As the price of whole genome sequencing continues to fall, more patients and healthcare providers are utilizing genetic data to inform treatment decisions, particularly in oncology, where genetic mutations often guide therapy choices. This shift is expanding the market for precision therapies and companion diagnostics, creating new opportunities for pharmaceutical and biotechnology companies.

The increasing prevalence of chronic diseases is another significant driver of the precision medicine market. As rates of cancer, diabetes, cardiovascular disease, and other chronic conditions continue to rise globally, there is a growing need for more effective and targeted treatments. Precision medicine offers the potential to deliver more personalized care for patients with these conditions, improving outcomes and reducing the trial-and-error approach often associated with conventional treatments. In oncology, for example, precision medicine has led to the development of targeted therapies that attack specific cancer-causing mutations, resulting in more effective and less toxic treatments compared to traditional chemotherapy.

Pharmaceutical companies are also driving market growth by investing heavily in the development of targeted therapies and precision-based drugs. The growing use of biomarkers and companion diagnostics is allowing drug developers to design treatments that are tailored to specific genetic or molecular profiles. This targeted approach increases the likelihood of successful clinical outcomes and reduces the risks of adverse reactions, leading to more efficient drug development processes. Additionally, the rise of immunotherapy and gene therapies, which are designed to treat specific patient populations, is contributing to the expansion of precision medicine applications across various therapeutic areas.

Lastly, the integration of artificial intelligence (AI) and machine learning into healthcare is accelerating the adoption of precision medicine. AI-driven tools are helping clinicians and researchers analyze large datasets, including genetic information, clinical records, and lifestyle data, to identify the most effective treatments for individual patients. These technologies are improving the speed and accuracy of diagnosis, enabling earlier intervention and personalized treatment plans. The increasing availability of health data from wearable devices and mobile health applications is also providing valuable insights into patient behavior, allowing for more comprehensive and continuous monitoring of health outcomes.

As the healthcare industry continues to prioritize personalized care and technology-driven solutions, the precision medicine market is expected to grow significantly in the coming years. These growth drivers, combined with ongoing advancements in genomics, AI, and biotechnology, are paving the way for more targeted, effective, and patient-centered healthcare solutions.

SCOPE OF STUDY:

The report analyzes the Precision Medicine market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Application (Diagnostics, Therapeutics); End-Use (Clinical Laboratories, Hospitals, Home Care, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â